Elosulfase Alfa (Vimizim®)

Elosulfase alfa (Vimizim) is covered only for the FDA‑approved indication MPS IVA (Morquio A) when diagnosis is confirmed by deficient N‑acetylgalactosamine‑6‑sulfatase activity or a pathogenic GALNS gene mutation and is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist; approvals are for 12 months and dosing is limited to up to 2 mg/kg IV no more frequently than once weekly. Non‑FDA indications are excluded, and coverage requires documentation of the confirmatory lab/genetic test, specialist prescribing/consultation, and fulfillment of applicable safety and coverage criteria.

"Treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) — FDA‑approved indication."

Sign up to see full coverage criteria, indications, and limitations.